# Study of NEO-201 in Solid Tumors Expansion Cohorts

Source: https://onco.cc/trials/nct03476681/  
OnCo record `nct03476681` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Precision Biologics, Inc, active and no longer recruiting.

## Summary

Study of NEO-201 in Solid Tumors Expansion Cohorts is a phase 1/2 interventional study registered as NCT03476681 by Precision Biologics, Inc, with 121 participants planned, started 2019-01-18 and due to reach its primary completion in 2026-06-17. Interventions recorded: NEO-201 in combination with pembrolizumab. Conditions listed: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03476681
- Phase: 1/2
- Setting: Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors
- Sponsor: Precision Biologics, Inc
- Enrolled: 121

## Sources

- ClinicalTrials.gov NCT03476681: https://clinicaltrials.gov/study/NCT03476681

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct03476681.json